TECH RSI

What is TECH?

Bio-Techne Corp. has an impressive history that started back in 1976 in Minneapolis under the name Techne Corporation. Over the decades, it evolved from a niche reagent supplier into a global life sciences giant. Today, they effectively serve as the picks and shovels provider for the biotechnology and pharmaceutical industries. Their business model is incredibly resilient, focusing on high-margin, consumable products that are deeply integrated into the workflows of academic labs and drug developers alike.

The company operates through two primary segments: Protein Sciences and Diagnostics and Genomics. Their R&D Systems brand is widely considered the gold standard for high-quality proteins, antibodies, and ELISA kits. Beyond reagents, they own the ProteinSimple line, which revolutionized protein analysis by automating complex processes like western blotting. On the diagnostic side, their ExosomeDx platform provides non-invasive liquid biopsies, which is a massive growth area for early cancer detection and monitoring.

Significant milestones include their 2014 rebranding and a strategic pivot toward aggressive acquisitions that expanded their reach into spatial biology and molecular diagnostics. This strategy has paid off, as Bio-Techne maintains some of the best gross margins in the industry. Their financial standing is characterized by steady organic growth and a strong balance sheet that allows for continued reinvestment in research and development.

Looking toward 2026, the strategic outlook is centered on three high-growth pillars: cell and gene therapy, proteomics, and spatial biology. They are rapidly scaling their GMP-grade reagent production to meet the demands of the booming cell therapy market. By 2026, Bio-Techne expects to be the primary partner for automated, high-throughput protein analysis in clinical settings. Their focus on recurring revenue from consumables and their expansion into emerging international markets should drive significant value. They are positioning themselves to be the backbone of the next generation of personalized medicine and therapeutic discovery.

What is RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and magnitude of price changes. Developed by J. Welles Wilder, RSI ranges from 0 to 100 and helps traders identify overbought or oversold conditions in an asset.

For TECH, monitoring the RSI provides valuable insights into potential trend reversals and entry/exit points. When the RSI drops below 30, Bio-Techne Corp. is typically considered oversold, suggesting the asset may be undervalued. Conversely, an RSI above 70 indicates overbought conditions.

Understanding TECH RSI Signals

• Oversold (RSI below 30): When TECH RSI falls below 30, it suggests the asset may have been sold off excessively and could be due for a bounce. This is often viewed as a potential buying opportunity, though it's important to consider other factors and not rely solely on RSI.
• Overbought (RSI above 70): An RSI above 70 indicates TECH may be overbought, potentially signaling a pullback or consolidation phase. Traders often use this as a signal to take profits or wait for better entry points.
• Divergences: When TECH price makes new highs or lows but RSI doesn't confirm these moves, it can signal weakening momentum and a possible trend reversal.

Daily vs Weekly RSI for TECH

This page displays both daily and weekly RSI for TECH. The daily RSI responds quickly to short-term price movements, making it useful for day traders and swing traders. The weekly RSI provides a broader perspective on momentum trends, helping longer-term investors identify major oversold or overbought conditions.

By analyzing both timeframes together, you can better understand Bio-Techne Corp.'s momentum at multiple levels and make more informed trading decisions.

Historical RSI Oversold Analysis

Above, we track historical instances when TECH RSI dropped below 30 (oversold territory). Reviewing these past oversold levels helps identify patterns and understand how Bio-Techne Corp. has historically responded to oversold conditions. Many traders use these historical reference points to gauge potential support levels and timing for entry positions.